S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
The perfect AI stock under $10 (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
The perfect AI stock under $10 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
The perfect AI stock under $10 (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
The perfect AI stock under $10 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
The perfect AI stock under $10 (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
The perfect AI stock under $10 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
The perfect AI stock under $10 (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
The perfect AI stock under $10 (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast

resTORbio (TORC) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

TORC vs. VCNX, EQ, IOBT, ANVS, BTAI, ALLK, BRNS, CMRX, CTMX, and CARM

Should you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Vaccinex (VCNX), Equillium (EQ), IO Biotech (IOBT), Annovis Bio (ANVS), BioXcel Therapeutics (BTAI), Allakos (ALLK), Barinthus Biotherapeutics (BRNS), Chimerix (CMRX), CytomX Therapeutics (CTMX), and Carisma Therapeutics (CARM). These companies are all part of the "medical" sector.

resTORbio vs.

resTORbio (NASDAQ:TORC) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

resTORbio received 18 more outperform votes than Vaccinex when rated by MarketBeat users. Likewise, 67.14% of users gave resTORbio an outperform vote while only 60.00% of users gave Vaccinex an outperform vote.

CompanyUnderperformOutperform
resTORbioOutperform Votes
141
67.14%
Underperform Votes
69
32.86%
VaccinexOutperform Votes
123
60.00%
Underperform Votes
82
40.00%

resTORbio has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Vaccinex has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

46.2% of resTORbio shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 11.8% of resTORbio shares are owned by company insiders. Comparatively, 51.3% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

resTORbio's return on equity of -78.12% beat Vaccinex's return on equity.

Company Net Margins Return on Equity Return on Assets
resTORbioN/A -78.12% -71.63%
Vaccinex N/A -2,667.31%-475.55%

Vaccinex has higher revenue and earnings than resTORbio. resTORbio is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
resTORbioN/AN/A-$82.74M-$2.41-1.18
Vaccinex$280K28.13-$19.82M-$84.56-0.10

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
resTORbio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Vaccinex
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

In the previous week, Vaccinex had 10 more articles in the media than resTORbio. MarketBeat recorded 10 mentions for Vaccinex and 0 mentions for resTORbio. Vaccinex's average media sentiment score of 0.04 beat resTORbio's score of 0.00 indicating that Vaccinex is being referred to more favorably in the news media.

Company Overall Sentiment
resTORbio Neutral
Vaccinex Neutral

Summary

Vaccinex beats resTORbio on 7 of the 13 factors compared between the two stocks.


Get resTORbio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TORC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TORC vs. The Competition

MetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$103.89M$6.65B$4.97B$7.37B
Dividend YieldN/A2.74%2.91%3.86%
P/E Ratio-1.579.2495.3014.70
Price / SalesN/A796.443,262.61154.77
Price / CashN/A18.3289.1453.45
Price / Book1.274.414.284.56
Net Income-$82.74M$156.18M$112.46M$207.29M

resTORbio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCNX
Vaccinex
0.8785 of 5 stars
$8.35
-19.6%
N/A-91.2%$104.29M$280,000.00-1.3838Stock Split
News Coverage
High Trading Volume
EQ
Equillium
1.9591 of 5 stars
$3.00
+8.7%
$4.60
+53.3%
+142.7%$105.36M$15.76M-12.5045Positive News
High Trading Volume
IOBT
IO Biotech
3.3532 of 5 stars
$1.54
-3.1%
$8.33
+441.1%
-42.9%$101.46MN/A-0.6357Positive News
Gap Down
ANVS
Annovis Bio
1.9442 of 5 stars
$10.07
-3.5%
$34.25
+240.1%
-41.0%$106.54MN/A-2.365Negative News
Gap Down
BTAI
BioXcel Therapeutics
4.2662 of 5 stars
$3.51
flat
$23.57
+571.6%
-90.1%$106.63M$380,000.00-0.48183Analyst Report
Gap Down
ALLK
Allakos
4.5654 of 5 stars
$1.22
-2.4%
$9.42
+671.9%
-78.9%$106.73MN/A-0.64123
BRNS
Barinthus Biotherapeutics
1.049 of 5 stars
$2.61
+4.0%
$15.00
+474.7%
N/A$100.64M$44.70M-1.29107Gap Up
High Trading Volume
CMRX
Chimerix
4.2078 of 5 stars
$1.22
+6.1%
$8.00
+555.7%
-24.2%$108.45M$33.82M-1.2789High Trading Volume
CTMX
CytomX Therapeutics
4.2267 of 5 stars
$1.47
flat
$2.73
+85.7%
-35.8%$98.48M$53.16M-3.27116Positive News
CARM
Carisma Therapeutics
0.9624 of 5 stars
$2.41
+4.8%
$10.00
+314.9%
N/A$97.27M$40M-0.64N/AUpcoming Earnings
Gap Down

Related Companies and Tools

This page (NASDAQ:TORC) was last updated on 2/22/2024 by MarketBeat.com Staff